Suven begin Phase I trials of 5-HT6 antagonist SUVN-502

Suven are to begin Phase I trials of 5-HT6 antagonist SUVN-502 intended for the treatment of Alzheimer’s disease.

GSK publish series of Tricyclic Azepine derivative 5HT6 antagonists

GSK have published a  series of Tricyclic Azepine derivative 5HT6 antagonists

Suvens 5-HT6 antagonist effective in Alzheimer models

Data presented at ICAD-2008 show Suven’s 5-HT6 antagonist SUVN-502 to be effective in preclinical models of Alzheimer’s

Memory Pharmaceuticals report positive preclinical data for 5-HT6 antagonist

Alzheimer’s Association International Conference show Memory Pharmaceutical’s 5-HT6 antagonist MEM 68626 to demonstate effecacy in animal models of cognition

Lillys long acting injection olanzapine shows similar profile to Zyprexa

Data prsented at the Schizophrenia International Research Society meeting show Lilly’s long acting injection (LAI) formulation of olanzapine to demonstrate similar efficacy and safety to Zyprexa.

MEM 68626 selected as lead 5-HT6 Antagonist for the treatment of cognitive disorders and obesity

Memory Pharmaceuticals has selected MEM-68626 as its lead 5-HT6 Antagonist for the treatment of cognitive disorders and obesity